Sun Pharma to test pancreatitis drug in Covid-19 patients in India

Drugmaker Sunshine Pharmaceutical Industries Ltd mentioned on Friday it has been given Indian regulatory acceptance

Drugmaker Sunshine Pharmaceutical Industries Ltd mentioned on Friday it has been given Indian regulatory acceptance to start clinical trials of a pancreatitis drug in Covid-19 sufferers.

The firm joins other Indian drugmakers Glenmark Prescribed drugs Ltd and Strides Pharma Science Ltd that are conducting trials in India for potential medications for Covid-19, which at this time has no approved cure or vaccine.

Sunshine Pharma mentioned below the pancreatitis drug, nafamostat mesilate, has been “identified as a potential prospect for Covid-19 sufferers by researchers at College of Tokyo and Leibniz Institute for Primate Investigate, Germany”.

The firm mentioned it has initiated producing of the energetic pharmaceutical component (API) and the completed merchandise of the drug using technological innovation from its unit, Pola Pharma Japan.

In April, the College of Tokyo declared plans for a trial of nafamostat mesilate and camostat mesilate, a relevant drug, accredited in Japan and South Korea to deal with persistent pancreatitis.

Sunshine Pharma shares obtained soon after the announcement, and shut up 3.3% at 474.25 rupees. Shares in Indian drugmakers have been on a tear this year, with the Nifty pharma index growing 21.5% so far.